Intra-cellular Therapies, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Intra-Cellular Therapies (ITI) stockholders are set to vote on a proposed merger agreement with Johnson & Johnson, where ITI would become a wholly-owned subsidiary of J&J at $132 per share.
Intra-Cellular Therapies (ITCI) has announced a definitive agreement to be acquired by Johnson & Johnson, pending shareholder and regulatory approvals.
Johnson & Johnson will acquire Intra-Cellular Therapies for $132.00 per share in cash, totaling approximately $14.6 billion, to strengthen its neuroscience leadership and add CAPLYTA to its portfolio.
Intra-Cellular Therapies, Inc. will hold its annual stockholder meeting virtually on June 14, 2024, to vote on key proposals including the election of a director, approval of an equity incentive plan amendment, ratification of the auditor, and an advisory vote on executive compensation.
Intra-Cellular Therapies is asking stockholders to approve an amendment and restatement of its 2018 Equity Incentive Plan to increase the number of shares available for issuance.